Health · Pharma & Biotech · 7 hrs ago
EU medicines committee backs Cosentyx for adolescents with HS
A committee of the European Medicines Agency recommended Cosentyx for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa, or HS.
HS is a chronic skin disease that can cause painful abscesses, which may burst and leave scars.
The recommendation applies to adolescents whose condition has not responded well enough to conventional systemic treatment.
The committee's recommendation is not yet EU approval for this use.
If approved, the medicine would be available for a younger age group with this condition.
The European Commission is expected to decide within about two months.
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approving Cosentyx for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.
The recommendation covers adolescents whose active condition has not responded adequately to conventional systemic treatment.
Hidradenitis suppurativa is a chronic skin disease that can cause painful abscesses and scarring.
The European Commission is expected to decide on approval within about two months.
Novartis announced the recommendation on Friday evening.
- Who
- Novartis received the recommendation for its medicine Cosentyx.
- What
- The committee recommended EU approval for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.
- When
- Novartis announced it on Friday evening; the article was published on November 13, 2026.
- Where
- The European Union.
- Why
- The recommendation is for adolescents whose active condition has not responded adequately to conventional systemic treatment.
This story does not have two clearly opposing sides.
Cash.ch published its report on Novartis receiving the committee’s positive recommendation.
The European Commission is expected to decide on approval.
- Medicine
- Cosentyx
- Recommended age
- 12 years and older
- Condition
- Moderate to severe hidradenitis suppurativa
- Treatment history
- Conventional systemic treatment has not worked adequately
- Expected decision
- European Commission decision within about two months